<DOC>
	<DOCNO>NCT01236690</DOCNO>
	<brief_summary>Cinobufacini effect anticancer , improve liver function , elevation immunity little side effect , important significant patient hepatitis , liver cirrhosis hepatoma . Compared transarterial chemoembolization ( TACE ) , clinical effect cinobufacini non-inferior/ equivalent.Compared TACE , cinobufacini superior security .</brief_summary>
	<brief_title>Study Hepatoma Treated Perfusing Cinobufacin Through Hepatic Artery Combining Embolotherapy</brief_title>
	<detailed_description>Inclusion criterion : 1 . The sex limit , age:18-70 year old . 2 . The patient inoperable advanced hepatoma without serious disorder liver renal , tumor occupation &lt; 70 % 3 . The patient failure surgical intervention resection operation recidivist 4 . Hepatic function Child-pugh A、B 5 . All case definite final diagnosis imageology result MRI、CT 、B ultrasonic cytology result 6 . The patient 's prediction live time &gt; 6 month , tolerant TACE quality life ECOG score &lt; 3 7 . The patient participate clinical trial voluntarily already sign inform consent Exclusion criterion : 1 . Main portal vein obstruct completely . 2 . The occupation tumor 70 % 70 % whole liver 3 . The patient TACE antineoplaston 4 . After carcinosectomy patient prophylactic 5 . The patient renal inadequacy : Cr≥133 umol/L 6 . Severe cardiovascular disease 7 . The patient diseases influence proposal</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>1 . The sex limit , age:1870 year old ; 2 . The patient inoperable advanced hepatoma without serious disorder liver renal , tumor occupation &lt; 70 % ; 3 . The patient failure surgical intervention resection operation recidivist ; 4 . Hepatic function Childpugh A、B ; 5 . All case definite final diagnosis imageology result MRI、CT 、B ultrasonic cytology result ; 6 . The patient 's prediction live time &gt; 6 month , tolerant TACE quality life ECOG score &lt; 3 ; 7 . The patient participate clinical trial voluntarily already sign inform consent . 1 . Main portal vein obstruct completely ; 2 . The occupation tumour 70 % 70 % whole liver ; 3 . The patient recepted TACE antineoplaston ; 4 . After carcinosectomy patient prophylactic ; 5 . The patient renal inadequacy : Cr≥133 umol/L 6 . Severe cardiovascular disease ; 7 . The patient diseases influence proposal ; 8 . All body generally metabasis malignant neoplastic disease ; 9 . In process participation medicinal trial ; 10 . Gravidity , lactation , hypersensitiveness constitution already know adverse reaction taboo .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Transcatheter arterial embolization</keyword>
	<keyword>Cinobufacin injection</keyword>
	<keyword>hepatoma</keyword>
</DOC>